Topic
Tybamate
About: Tybamate is a research topic. Over the lifetime, 39 publications have been published within this topic receiving 247 citations.
Papers
Journal Article•
TL;DR: It appears that the spinal interneuronal site of action of tybamate alone may adequately explain the depression of spinal polysynaptic reflexes, and the findings suggest that the major site ofaction of diazepam is the brainstem reticular system.
Abstract: Diazepam and tybamate have previously been reported to depress spinal polysynaptic reflexes. The dose-response relationships for depressant actions of diazepam and tybamate on contralateral extensor reflexes were studied in midcollicular and acute spinal cats. The reflexes were readily depressed by small doses of diazepam in midcollicular preparations, whereas very large doses (100-fold) were required in spinal preparations. On the other hand, the doseresponse curves of tybamate-induced depression were practically identical in these two preparations. The effects of graded doses of diazepam and tybamate on mesencephalic reticular and spinal internuncial neuronal activity were also studied. Whereas approximately 0.05 mg/kg of diazepam was required to decrease the reticular neuronal activity 50%, 0.4 mg/kg was required to reduce spinal interneuronal activity to the same extent. These findings suggest that the major site of action of diazepam is the brainstem reticular system. Tybamate was found to act equally on the reticular neurons and spinal interneurons. It appears, however, that the spinal interneuronal site of action of tybamate alone may adequately explain the depression of spinal polysynaptic reflexes.
48 citations
20 citations
TL;DR: Tybamate produced significantly more improvement than placebo only at the final four-week evaluation, and the largest tybamate-placebo differences were observed on measures of somatic manifestations of free anxiety, followed by measures of bound anxiety such as phobic-obsessive-compulsive symptoms.
Abstract: Tybamate was evaluated in a controlled, double-blind study conducted with 126 anxious neurotic patients seen in general practice. Tybamate produced significantly more improvement than placebo only at the final four-week evaluation. The largest tybamate-placebo differences were observed on measures of somatic manifestations of free anxiety, followed by measures of bound anxiety such as phobic-obsessive-compulsive symptoms. Severity of initial symptomatology was related to the patient's response to tybamate but not to placebo; those patients who were initially sickest improved significantly more than patients who were initially less sick.
20 citations
Journal Article•
TL;DR: Using a reproducible screening procedure for rat liver cytochrome P450 isoenzyme induction/inhibition, five dicarbamate drugs were compared with sodium phenobarbital and found to be from 25 to 100 times less potent hepatic cytochrom P450 inducers than phenobarBital.
Abstract: Using a reproducible screening procedure for rat liver cytochrome P450 isoenzyme induction/inhibition, five dicarbamate drugs (meprobamate, mebutamate, carisoprodol, tybamate, and W-554) were compared with sodium phenobarbital and found to be from 25 to 100 times less potent hepatic cytochrome P450 inducers than phenobarbital.
18 citations
TL;DR: The relatively poor correlation between blood levels of central depressant drugs and clinical symptoms may be related in part to the difficulty of measuring relevant effects in normal men, and in larger part, it may be due to the fact that social and personal factors more strongly influence the appearance of clinical effects from mild central depressants than do serum levels of the drugs.
Abstract: Experiments are reported in which single therapeutic doses of central depressant drugs were given to normal volunteers with simultaneous measurement of blood levels of drug and clinical effects. In the case of pentobarbital, only one of nine possible correlations was significant; after eight hours, high serum levels of pentobarbital were correlated with high aggressive scores on a mood scale. In the case of meprobamate, none of six possible correlations at two time periods was significant, although the relationship between sleepy scores and high plasma levels approached significance both times. This relationship was confirmed for meprobamate in a third study, in which the presence of sleepiness as a symptom was associated with significantly higher levels of drug than its absence. Similar findings applied to tybamate in regard to the symptom of drowsiness. The relatively poor correlation between blood levels of central depressant drugs and clinical symptoms may be related in part to the difficulty of measuring relevant effects in normal men. In larger part, however, it may be due to the fact that social and personal factors more strongly influence the appearance of clinical effects from mild central depressants than do serum levels of the drugs.
17 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 1985 | 1 |
| 1975 | 1 |
| 1972 | 1 |
| 1971 | 4 |
| 1970 | 1 |
| 1969 | 4 |